Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine
详细信息 查看全文
- 作者：Kelly E. Huibregtsea ; 1 ; kelly.huibregtse@ucsf.edu" class="auth_mail" title="E-mail the corresponding author ; Kieuhoa T. Vob ; Kieuhoa.Vo@ucsf.edu" class="auth_mail" title="E-mail the corresponding author ; Steven G. DuBoisc ; Steven_Dubois@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Stephanie Fetzkod ; fetzko@bcm.edu" class="auth_mail" title="E-mail the corresponding author ; John Neuhause ; John.Neuhaus@ucsf.edu" class="auth_mail" title="E-mail the corresponding author ; Vandana Batraf ; Batrav@email.chop.edu" class="auth_mail" title="E-mail the corresponding author ; John M. Marisf ; Maris@email.chop.edu" class="auth_mail" title="E-mail the corresponding author ; Brian Weissg ; Brian.Weiss@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; Araz Marachelianh ; AMarachelian@chla.usc.edu" class="auth_mail" title="E-mail the corresponding author ; Greg A. Yaniki ; gyanik@med.umich.edu" class="auth_mail" title="E-mail the corresponding author ; Katherine K. Matthayb ; kate.matthay@ucsf.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Neuroblastoma ; Paediatrics ; Cancer ; MIBG ; I-metaiodobenzylguanidine ; SMN ; Second malignancy ; Chemotherapy ; Solid tumour ; Survivorship
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：66
- 期：Complete
- 页码：144-152
- 全文大小：368 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Multi-institutional review of neuroblastoma patients treated with iodine-131 metaiodobenzylguanidine (131I-MIBG) therapy.
- class="label">•
Competing risk approach used to find cumulative incidence of second malignant neoplasm (SMN) from first MIBG.
- class="label">•
Cumulative risk of SMN after MIBG therapy was 14% at 10 years.
- class="label">•
Results similar to risk after myeloablative therapy; no dose-dependent increase.